ADVI Analysis: MACPAC January 2024 Meeting

Pharmaceuticals and Biotech Pharmaceuticals and Biotech

January 30, 2024

MACPAC held a meeting January 24-25 (link). The following relevant topics were discussed:

  • Denials and Appeals in Medicaid Managed Care
  • State Medicaid Agency Contracts (SMAC) Interviews with Key Stakeholders
  • Findings from Expert Roundtable on Evaluating the Effects of Medicaid Payment Changes on Access to Physician Services
  • Medicaid Coverage of Physician-Administered Drugs
  • Vote on Recommendations for the March Report to Congress
  • Medicare Savings Programs (MSPs): Enrollment Trends

ADVI Angle

Key takeaways from the January meeting include:

  • Denials and Appeals in Medicaid Managed Care
    • Commissioners agreed with most of the recommendations, but much of their discussion focused on whether to recommend an external appeals review process for denied claims, with many commissioners split due to monetary and complexity concerns.
  • SMAC Interviews with Key Stakeholders
    • Commissioners were concerned with limited state resources to utilize and enforce SMAC authorities and were interested in improving state capacity.
  • Findings from Expert Roundtable on Evaluating the Effects of Medicaid Payment Changes on Access to Physician Services
    • Key findings from the roundtable: 1) Physicians are less likely to serve Medicaid patients 2) it’s unclear if payment increases could change that, and 3) provider consolidation may help Medicaid beneficiaries. Commissioners identified multiple areas for future study.
  • Medicaid Coverage of Physician-Administered Drugs
    • Key findings from presentation: 1) There are several challenges in managing PAD use and spending, 2) MACPAC staff estimates are likely underestimates as drugs included in bundled payments were not included in total spend calculations.
  • Vote on Recommendations for the March Report to Congress
    • Commissioners voted in favor of all recommendations, with some discussion around recommendations 2.1 and 2.6.
  • Medicare Savings Programs (MSPs): Enrollment Trends
    • Key takeaway from presentation: MSP enrollment numbers have grown, indicating that efforts made by the federal and state governments to increase enrollment may have succeeded.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Pharmaceuticals and Biotech

ADVI Analysis: MACPAC October 2024 Meeting

MACPAC held a meeting on October 31 and November 1, 2024 (link). The following relevant topics were discussed: ADVI Angle …

November 11, 2024

Inflation Reduction Act Pharmaceuticals and Biotech State Policy

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

On October 4, 2024, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “HHS Notice of …

Brenna Raines, MHA
October 21, 2024

Pharmaceuticals and Biotech

ADVI Analysis: MedPAC October 2024 Meeting

MedPAC held a meeting on October 10-11, 2024 (link). The following relevant topics were discussed: ADVI Angle Key takeaways from …

October 21, 2024

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: CMS Finalizes Guidance on IPAY 2027 Negotiation and MFP Implementation for 2026/27

On October 2, 2024, CMS issued final guidance on the Medicare Drug Price Negotiation Program for IPAY 2027 and Manufacturer …

Lindsay Bealor Greenleaf, JD, MBA
October 11, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases Medicaid Drug Rebate Program Final Rule

On September 20, 2024, the Centers for Medicare and Medicaid Services (CMS) released a Final Rule titled “Misclassification of Drugs, …

Lindsay Bealor Greenleaf, JD, MBA
September 27, 2024

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.